comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, Health Comparing GLP-type therapies for weight
Description
We can usher in a new age of GLP-1 regulation by tapping into nature's resources, giving patients more alternatives for managing T2D that are safe, effective, and well-tolerated
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
The primary outcome was gestational weight gain, calculated as the difference between the last recorded weight within 1 week of delivery and prepregnancy weight
For the present analysis, the team selected a subset of 111,646 overweight and obese women (BMI 25, median age 61 years) aged 45-80 years
What is Mounjaro
How often do you need to take Mounjaro compared to Ozempic for weight loss
